Generalized Anxiety Disorder Research Report 2022: Market Insight, Epidemiology and Market Forecast to 2032 - Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

·7 min read

DUBLIN, May 25, 2022--(BUSINESS WIRE)--The "Generalized Anxiety Disorder - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.

The Generalized Anxiety Disorder market report provides current treatment practices, emerging drugs, Generalized Anxiety Disorder market share of the individual therapies, current and forecasted Generalized Anxiety Disorder market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Generalized Anxiety Disorder treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Treatment

It covers the details of conventional and current medical therapies available in the Generalized Anxiety Disorder market for the treatment of the condition. It also provides Generalized Anxiety Disorder treatment algorithms and guidelines in the United States, Europe, and Japan.

Generalized Anxiety Disorder Epidemiology

The Generalized Anxiety Disorder epidemiology division provide insights about historical and current Generalized Anxiety Disorder patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Generalized Anxiety Disorder epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Generalized Anxiety Disorder Drug Chapters

Drug chapter segment of the Generalized Anxiety Disorder report encloses the detailed analysis of Generalized Anxiety Disorder marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Generalized Anxiety Disorder clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Generalized Anxiety Disorder treatment.

Generalized Anxiety Disorder Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Generalized Anxiety Disorder treatment.

Generalized Anxiety Disorder Market Outlook

The Generalized Anxiety Disorder market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Generalized Anxiety Disorder market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Generalized Anxiety Disorder market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Generalized Anxiety Disorder market in 7MM is expected to change in the study period 2019-2032.

Key Findings

This section includes a glimpse of the Generalized Anxiety Disorder market in 7MM.

The United States Market Outlook

This section provides the total Generalized Anxiety Disorder market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Generalized Anxiety Disorder market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Generalized Anxiety Disorder market size and market size by therapies in Japan is also mentioned.

Generalized Anxiety Disorder Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Generalized Anxiety Disorder market or expected to get launched in the market during the study period 2019-2032. The analysis covers Generalized Anxiety Disorder market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Generalized Anxiety Disorder Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Generalized Anxiety Disorder key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Generalized Anxiety Disorder emerging therapies.

Reimbursement Scenario in Generalized Anxiety Disorder

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL-Views

To keep up with current market trends, we take KOLs and SME's opinion working in Generalized Anxiety Disorder domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Generalized Anxiety Disorder market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive and Market Intelligence analysis of the Generalized Anxiety Disorder Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Generalized Anxiety Disorder Report Insights

  • Patient Population

  • Therapeutic Approaches

  • Generalized Anxiety Disorder Pipeline Analysis

  • Generalized Anxiety Disorder Market Size and Trends

  • Market Opportunities

  • Impact of upcoming Therapies

Generalized Anxiety Disorder Report Key Strengths

  • 11 Years Forecast

  • 7MM Coverage

  • Generalized Anxiety Disorder Epidemiology Segmentation

  • Key Cross Competition

  • Highly Analyzed Market

  • Drugs Uptake

Generalized Anxiety Disorder Report Assessment

Current Treatment Practices

  • Unmet Needs

  • Pipeline Product Profiles

  • Market Attractiveness

  • Market Drivers and Barriers

Key Topics Covered:

1. Key Insights

2. Executive Summary of Generalized Anxiety Disorder

3. Competitive Intelligence Analysis for Generalized Anxiety Disorder

4. Generalized Anxiety Disorder: Market Overview at a Glance

4.1. Generalized Anxiety Disorder Total Market Share (%) Distribution in 2019

4.2. Generalized Anxiety Disorder Total Market Share (%) Distribution in 2032

5. Generalized Anxiety Disorder: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Generalized Anxiety Disorder Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Generalized Anxiety Disorder Epidemiology Scenario in the 7MM (2019-2032)

7.4. United States Epidemiology

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.2. France Epidemiology

7.5.3. Italy Epidemiology

7.5.4. Spain Epidemiology

7.5.5. United Kingdom Epidemiology

7.5.6. Japan Epidemiology

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Generalized Anxiety Disorder Treatment and Management

8.2. Generalized Anxiety Disorder Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Generalized Anxiety Disorder Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

13. Generalized Anxiety Disorder: Seven Major Market Analysis

13.1. Key Findings

13.2. Generalized Anxiety Disorder Market Size in 7MM

13.3. Generalized Anxiety Disorder Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Generalized Anxiety Disorder Total Market Size in the United States

15.1.2. Generalized Anxiety Disorder Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.4. France Market Size

15.5. Italy Market Size

15.6. Spain Market Size

15.7. United Kingdom Market Size

15.8. Japan Market Outlook

16. Access and Reimbursement Overview of Generalized Anxiety Disorder

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

Companies Mentioned

  • Bionomics

  • Pherin Pharmaceuticals

  • VistaGen Therapeutics

  • BioHaven Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/r2zq9n

View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005596/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting